Whiteoak Capital Pharma and Healthcare Fund - Direct Plan - Growth vs HDFC Pharma and Healthcare Fund Direct Plan IDCW Reinvestment
NAV, returns and costs — not a recommendation.
 Whiteoak Capital Pharma and Healthcare Fund - Direct Plan - Growth |  HDFC Pharma and Healthcare Fund Direct Plan IDCW Reinvestment | |
|---|---|---|
| NAV | ₹17.282 | ₹21.944 |
| NAV date | 2026-09-30 | 2026-09-30 |
| 1 year | +24.16% | +27.80% |
| 3 year (p.a.) | +22.95% | +30.22% |
| 5 year (p.a.) | +22.95% | +30.22% |
| Expense ratio | 0.60% | 0.92% |
| Fund size | ₹664.02 Cr | ₹2362.44 Cr |
| Risk | — | — |
| Category | Sectoral Pharma and Healthcare | Sectoral Pharma and Healthcare |
Past performance does not guarantee future returns. Mutual fund investments are subject to market risks.